IDEAYA Biosciences Inc (NAS:IDYA)
$ 26.77 -0.68 (-2.48%) Market Cap: 2.31 Bil Enterprise Value: 1.47 Bil PE Ratio: 0 PB Ratio: 1.96 GF Score: 30/100

IDEAYA Biosciences Inc at Citi Virtual Oncology Leadership Summit Transcript

Feb 21, 2023 / 02:00PM GMT
Release Date Price: $17.4 (-1.64%)
Yigal Nochomovitz
Citigroup - Analyst

Okay. Welcome, everyone. I'm Yigal Nochomovitz, one of the biotech analysts at Citi. This is our Oncology Summit over the next three days. It's my pleasure to have with me Yujiro Hata, the Co-Founder, CEO, and President of IDEAYA Biosciences.

Welcome, Yujiro. Great to see you. I guess maybe to start with, obviously, a lot of people are familiar with your pipeline, but some maybe a little bit less familiar. So if you want to kick us off with a quick overview of IDEAYA, talk about your synthetic lethality platform, and then we can move into more detailed discussion of some of your programs. Thanks.

Yujiro Hata
IDEAYA Biosciences, Inc. - President & CEO

Great. Thanks so much again for the kind introduction. And thank you to Citi for the opportunity to participate this year in your Oncology Summit. So IDEAYA was founded over seven years ago with a core focus to build the leading synthetic lethality-focused precision medicine oncology company.

Today, we have three clinical programs. Our most advanced is

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot